Cargando…

Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients

We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When administered ear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Birk, Navina K, Jain, Saniya, Massoud, Louis, Ramesh, Diya, Monday, Lea, Muma, Bruce, Williams, Jonathan, Alangaden, George, Ramesh, Mayur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214182/ https://www.ncbi.nlm.nih.gov/pubmed/35859992 http://dx.doi.org/10.1093/ofid/ofac282

Ejemplares similares

500. A Real-World Cohort Study of Bamlanivimab Versus Bamlanivimab-Etesevimab for Non-severe COVID-19
por: Monday, Lea, et al.
Publicado: (2021)

607. Candidemia: Role of T2Candida® compared to Bact/Alert Virtuo blood culture system in a real-world setting
por: Birk, Navina K, et al.
Publicado: (2023)

505. Bezlotoxumab Reduces Recurrence of Clostridium difficile Infection in Immunocompromised Patients: Early Experience at a Tertiary Care Center
por: Askar, Sally, et al.
Publicado: (2018)

Low- Versus High-Dose Methylprednisolone in Adult Patients With Coronavirus Disease 2019: Less Is More
por: Joshi, Seema, et al.
Publicado: (2021)

Vaccine coverage and factors associated with vaccine adherence in persons with HIV at an urban infectious disease clinic
por: Birk, Navina K., et al.
Publicado: (2023)

497. Moderate Versus High Dose Corticosteroids in Adult Patients with Severe COVID-19: Less Is More
por: Joshi, Seema, et al.
Publicado: (2021)

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
por: Huygens, Sammy, et al.
Publicado: (2022)

104. Evaluation of Vaccination Rates and Factors associated with Vaccine Uptake among People Living with HIV in Detroit, MI
por: Birk, Navina K, et al.
Publicado: (2022)

328. Universal PCR Testing- Is It Worth It?
por: Birk, Navina K, et al.
Publicado: (2022)

1145. Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 in the US
por: Cheng, Mindy M, et al.
Publicado: (2022)

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

Sotrovimab for COVID-19
Publicado: (2021)

Sotrovimab: First Approval
por: Heo, Young-A
Publicado: (2022)

T2Candida for the Diagnosis and Management of Invasive Candida Infections
por: Monday, Lea M, et al.
Publicado: (2021)

Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients
por: Gliga, Smaranda, et al.
Publicado: (2022)

Epidemiology, Risk Factors and Outcomes of Candida Empyema: A 5-Year Single-Centered Experience
por: Williams, Jonathan, et al.
Publicado: (2017)

510. Real-world Effectiveness of Sotrovimab for COVID-19: Evidence from United States (US) Administrative Claims Data
por: Bell, Christopher F, et al.
Publicado: (2023)

SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience
por: Totschnig, David, et al.
Publicado: (2022)

Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
por: Baldi, Federico, et al.
Publicado: (2023)

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
por: Razonable, Raymund R, et al.
Publicado: (2022)

458 Enterococcal Infections (EI) in Kidney Transplant (KT) Recipients – a Four Year Retrospective Review
por: Patel, Tejal, et al.
Publicado: (2014)

547. Risk Factors Associated with 30-Day Mortality in a Large Cohort of Patients who Received Remdesivir and Corticosteroids for Severe COVID-19
por: Gupta, Kartik, et al.
Publicado: (2021)

497. Safety and tolerability of 2000mg intravenous sotrovimab dose in immunocompromised participants uninfected with SARS-CoV-2 in the PROTECT-V trial
por: Dosanjh, Davinder, et al.
Publicado: (2023)

Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study
por: Ong, Sean W. X., et al.
Publicado: (2022)

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA
por: Cheng, Mindy M., et al.
Publicado: (2023)

344. VersaTrek versus Virtuo Blood Culture System’s Effect on Diagnostic Test Utilization and Patient Outcomes, a Quasi-Experimental Study
por: Dillon, William P, et al.
Publicado: (2022)

Impact of Female External Urinary Catheter on Indwelling Catheter Use and Catheter-Associated Urinary Tract Infection Rates
por: Monday, Lea, et al.
Publicado: (2021)

455 Enterococcal Infections (EI) in Liver Transplant (LT) Recipients- a 9 year retrospective review
por: Elbatta, Mohammad, et al.
Publicado: (2014)

441 Incidence and Risk Factors for Development of Liver Abscesses in Liver Transplant Recipients with Intra Abdominal Infections - a 10 year retrospective review
por: Aldeiri, Ahmad, et al.
Publicado: (2014)

56. Could Maturation Effect Contribute to In-hospital Mortality Improvement During COVID-19 Pandemic?
por: Maki, Gina, et al.
Publicado: (2020)

592. Antimicrobial Utilization in Solid Organ Transplant Recipients 12-Months Post-Transplantation
por: Parraga Acosta, Tommy J, et al.
Publicado: (2021)

Voriconazole-Resistant Penicillium oxalicum: An Emerging Pathogen in Immunocompromised Hosts
por: Chowdhary, Anuradha, et al.
Publicado: (2014)

593. Utility of Microbiologic Testing Obtained via Bronchoalveolar Lavage on Asymptomatic Lung Transplant Recipients: A Quality Improvement Study
por: Dillon, William, et al.
Publicado: (2021)

Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity
por: Gonzalez-Bocco, Isabel H., et al.
Publicado: (2023)

CO103 Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the National COVID Cohort Collaborative (N3C)
por: Bell, C., et al.
Publicado: (2023)

Sotrovimab: Emergence of acquired resistance: 4 case reports
Publicado: (2022)

Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation
por: Marcacci, Gianpaolo, et al.
Publicado: (2022)

325. Outcomes of Outpatient Parenteral Antimicrobial Therapy in the Solid Organ Transplant Population
por: Dillon, William P, et al.
Publicado: (2023)

Atypical presentation of maxillary osteomyelitis in an immunocompromised patient
por: Divyambika, CV, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rdpb76ppdrkqpamv5v0li96suu